Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Dr. Reddy's Laboratories Ltd (RDY) vs Takeda Pharmaceutical Co. (TAK)

Dr. Reddy's Laboratories Ltd and Takeda Pharmaceutical Co. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $59.2B against $10.0B — 5.9× the size. Takeda Pharmaceutical Co. trades at the lower P/E: 28.4× against 30.8×. Takeda Pharmaceutical Co. grew revenue faster over the last twelve months: 0.66% against −11.6%. Dr. Reddy's Laboratories Ltd has the higher net margin (9.81% vs 7.12%) and the higher return on invested capital (5.89% vs 2.88%). Both pay a dividend; Takeda Pharmaceutical Co. yields more (4.52% vs 0.66%). Across the 23 metrics below, Takeda Pharmaceutical Co. leads on 12 and Dr. Reddy's Laboratories Ltd on 11.

Valuation

Metric RDY TAK Drug Manufacturers Specialty & Generic median
P/E 30.85 28.36 20.14
P/S 2.79 1.99 2.25
P/B 2.35 1.25 1.90
Price to free cash flow 69.03 8.03 16.54
EV/EBITDA 15.92 10.48 12.29
EV/Sales 2.76 2.91 2.56
Earnings yield 3.24% 3.53% (2.99%)
Free cash flow yield 1.45% 12.46% 0.00%

Profitability

Metric RDY TAK Drug Manufacturers Specialty & Generic median
Gross margin 50.00% 65.85% 53.94%
Operating margin 10.91% 11.61% 0.00%
Net margin 9.81% 7.12% 0.00%
Free cash flow margin 4.05% 24.74% 0.00%
Return on equity 8.21% 4.42% (0.40%)
Return on assets 5.55% 2.15% (3.32%)
Return on invested capital 5.89% 2.88% 0.00%

Growth

Metric RDY TAK Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (11.60%) 0.66% 10.01%
EPS growth (last fiscal year) (30.38%) (244.86%) —
Revenue growth, 5-year CAGR 6.66% (0.21%) 6.74%
Net income growth, 5-year CAGR 14.08% 0.00% 0.00%

Health

Metric RDY TAK Drug Manufacturers Specialty & Generic median
Debt to equity 0.19 0.65 0.05
Current ratio 1.90 1.14 2.31
Net debt to EBITDA (0.15) 5.84 0.85

Dividend

Metric RDY TAK Drug Manufacturers Specialty & Generic median
Dividend yield 0.66% 4.52% 1.70%
Payout ratio 0.14 0.50 0.00

Size

Metric RDY TAK Drug Manufacturers Specialty & Generic median
Market cap 10.02b 59.16b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack